Background

Human chorionic gonadotropin (hCG) secreting placental tumors such as hydatidiform moles and choriocarcinomas have been found to be associated with hyperthyroidism [1] and HCG has been reported to increase TSH receptor expression, thyroid hormone secretion, iodide uptake, organification, adenylate cyclase, and deoxribonucleic acid synthesis in rat and also cultured human thyrocytes [2–4].

Luteinizing hormone is a glycoprotein hormone like TSH and has similar alpha subunit. In Carayon et al. study LH has been identified to increase thyroid adenylate cylase activity 65 times more potently than HCG in human thyroid membranes [5]. Also, in Yoshimura et al. study human LH has been found to be more potent than HCG in binding to the TSH receptor and stimulating adenylate cyclase [6]. As mentioned above, hCG and LH have thyrotropic effect on rat and human thyroid membrane.

Our hypotheses is increased LH levels might have a growth effect on thyroid gland in patients with polycystic ovary syndrome (PCOS). Polycystic ovary syndrome is a common endocrine disorder affecting at least five to 10% of women of reproductive age [7].

The goiter prevalence is more common in women than in men regardless of population [8]. However, there have been no data on increased thyroid volume or goitre prevalence in women with PCOS versus women with regular menstrual cycles. The higher incidence of thyroid diseases in women has been previously attributed to higher estradiol levels. Estradiol has been shown to enhance proliferative and mitogenic activities of thyroid cells [9, 10]. However, in recent years chronic estradiol treatment has been shown to reduce volume densities of thyroid follicles, follicular epithelium and thyroid gland volume [11, 12]. Despite the enhancing effect of estradiol on thyroid cells, the reducing effect of chronic estradiol treatment on thyroid volume can be related to LH suppression.

It has been known that patients with PCOS have elevated LH levels [13, 14] and also have higher gonadotrophin-releasing hormone (GnRH)-stimulated LH concentrations in comparison to healthy controls [15]. In relation to present hypotheses in Knudsen et al. study 3712 women were evaluated and found that oral contraceptives were related with a lower thyroid volume and reduced risk of goiter. In this study the oral contraceptives users had goitre four times less common than non-users [12]. In this case, the LH suppression with oral contraceptives including estradiol might be the factor for decreased thyroid volumes consistent with present hypotheses. However, this literature applies to general population of women, and not to women with PCOS and additionally, in literature search there is no data that the use oral contraceptives in women with PCOS is associated with reduction of thyroid volume or lower goitre prevalence.

In the recent hypotheses increased LH levels might provide a stimulus for growth on thyroid and alter thyroid function. Therefore patients with PCOS who had elevated LH levels should be treated by combined estradiol pills such as estrogen-progestin contraceptives for suppression of LH secretion. Further studies are needed to evaluate the association between LH, LH suppression and thyroid volume in patients with PCOS.